Currently, there are no FDA-accepted therapies for fibrotic disease, and we look forward to better understanding the potential therapeutic good thing about an LPA1 antagonist in this region of medication. While there are no LPA1 selective antagonists authorized for therapeutic use, there is a strong scientific rationale because of this as a focus on for novel treatment in a variety of fibrotic diseases including scleroderma and idiopathic pulmonary fibrosis.. Amira initiates AM152 Phase 1 clinical study for fibrotic diseases Amira Pharmaceuticals, Inc. Announced today that it has initiated a Phase 1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects. We are thrilled to begin our trip exploring the therapeutic value of AM152, a novel anti-fibrotic agent potentially.‘This past year we found that SIV triggers some of the same biological pathways of cell loss of life and inflammation as these other diseases,’ says Sheila Barber, Ph.D., associate professor of comparative medication. ‘Testing minocycline in our animal model of HIV infection really was a logical next thing.’ A multicenter medical trial is being planned to check whether minocycline gets the same effects in HIV-infected people since it does in SIV-infected monkeys, nonetheless it is not expected to start until next year sometime. ‘It is prematurily. To recommend minocycline for patients,’ emphasizes Ned Sacktor, M.D., a co-employee professor of neurology at the Johns Hopkins Bayview Medical Center who wasn’t involved with the current study, but who is one of the physicians setting up the medical trial.